Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions

Cancer Investigation

Volumn 27, Issue 5, 2009, Pages 489-495

  Tang, Shou Ching ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Anthracyclines; Clinical trials; Disease free and overall survival; Docetaxel; Dosage; Early breast cancer; Meta analysis; Paclitaxel; Scheduling and safety; Sequencing; Taxanes

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ADD ON THERAPY; ANEMIA; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSENSUS; DRUG EFFICACY; EARLY CANCER; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; THROMBOEMBOLISM; ADJUVANT CHEMOTHERAPY; BREAST TUMOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; TAXOIDS;

EID: 67449105933     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802427943     Document Type: Review

References (29)

1. Nowak, A.K.; Wilcken, N.R.; Stockler, M.R.; et al. Systematic review of taxane-containing versus nontaxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004, 5(6), 372-380.
2. Bria, E.; Nistico, C.; Cuppone, F.; et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006, 106(11), 2337-2344. (Pubitemid 43787656)
3. Ward, S.; Simpson, E.; Davis, S.; et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007, 11(40), 1-144.
4. Ferguson, T.; Wilcken, N.; Vagg, R.; et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews 2007, (4). Art. No.: CD004421. DOI: 10.1002/14651858.CD004421.pub2.
5. De Laurentiis, M.; Giuseppe, C.; D'Agostino, D.; et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008, 1(26), 44-52.
6. Buzdar, A.U.; Singletary, S.E.; Valero, V.; et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002, 8, 1073-1107.
7. Henderson, I.C.; Berry, D.A.; Demetri, G.D.; et al. Improved outcomes from adding sequential paclixaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21, 976-983.
8. Mamounas, E.P.; Bryant, J.; Lembersky, B.; et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23, 3686-3696
9. Martin, M.; Rodriguez-Lescure, A.; Ruiz, A.; et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC90 versus 4 cycles of FEC90 followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trail. Breast Cancer Res Treat 2005a, 94, 39.
10. Roche, H.; Fumoleau, P.; Spielmann, M.; et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patient: the FNCLCC PACS 01 Trial. J Clin Oncol 2006, 24, 5664-5671.
11. Martin, M.; Pienkowski, T.; Mackey, J.; et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005b, 352, 2303-2313.
12. Goldstein, L.J.; O'Neill, A.; Sparano, J. Phase III AT (doxorubicin/docetaxel) v AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node-positive and high risk node-positive and high risk node-negative breast cancer. J Clin Oncol 2005, 23, 16s (Suppl, abstr 512).
13. Gianni, L.; Baselga, J.; Eiermann, W. European Cooperative Trail in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol 2005, 23, 16s (Suppl, abstr 513)
14. Nabholtz, J.M.; Tonkin, K.; Smylie, M.; et al. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. Semin Oncol 1999, 26(1 Suppl 3), 10-16.
15. Perez, E.A. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest 2001, 19(2), 155-164. (Pubitemid 32233787)
16. Eiermann, W.; Pienkowski, T.; Crown, J.; et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC-T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Breast Cancer Res Treat 2005, 94(Suppl, abstr 1069).
17. Hudis, C.; Citron, M.; Berry, D.; et al. Five year follow-up if INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat 2005, 94, 39(Suppl, abstract 41).
18. Moebus, V.J.; Lueck, H.J.; Thomssen, C.; et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional schedule chemotherapy in high-risk breast cancer patients (≥ 4+ LN). Mature results of an AGO-trial. Breast Cancer Res Treat 2006, 100(Suppl 1), S20 Abstract 43.
19. Burnell, M.; Levine, M.; Chapman, J.A.; et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Res Treat 2006, 100(Suppl 1) Abstract 53.
20. Sparano, J.; Wang, M.; Martino, S.; et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358(16), 1663-1671. (Pubitemid 351549913)
21. Hayes, D.F.; Thor, A.D.; Dressler, L.G.; et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357(15), 1496-1506. (Pubitemid 47572635)
22. Ellis, P.A.; Barrett-Lee, P.J.; Bloomfield, D. Preliminary results of the UK taxotere as adjuvant chemotherapy (TACT) Trial. Breast Cancer Res Treat 2007, 106 (Suppl, abstr 78).
23. Crown, J.P.; Francis, P.; Di Leo, A.; et al. Docetaxel given concurrently with or sequentially to anthracycline-based adjuvant therapy for patients with node-positive breast cancer, in comparison with non-T adjRx: first results of the BIG 2-98 trial at 5 years median follow-up. Proc Am Soc Clin Oncol 2006, 24, 7s (Abstract LBA519).
24. Kummel, S.; Rezai, M.; Kimmig, R.; et al. Dose-dense chemotherapy for primary breast cancer. Curr Opin Obstet Gynecol 2007, 1, 75-81. (Pubitemid 46095877)
25. Martin, M.; Mackey, J.; Vogel, C. Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast 2007, 16(Suppl 2), S127-S131. (Pubitemid 350028574)
26. Slamon, D.J.; Mackey, J.; Robert, N.; et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. Breast Cancer Res Treat 2007, 106(Suppl 1) (Abstract 13).
27. Jones, S.; Holmes, F.; O'Shaughnessy, J.; Blum, J.; et al. Extended follow-up and analysis by age of the US oncology adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 2007, 106 (Suppl, abstr 12).
28. Tang, S.-C. Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer. Can Invest 2008, in print.
29. Tang, S.-C. Molecular predictive markers of tubulin-targeting agents in breast cancer. Clinical Breast Cancer 2008, 8(Suppl 22), S79-S84.